Clinical Trials on Tinea Cruris in Norway

Total 6 results

Novartis

Completed

Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis

Onychomycosis

France, Finland, Germany, Hungary, Iceland, Norway, Poland, Russian Federation, Spain, Turkey
Polichem S.A.
Almirall, S.A.

Withdrawn

Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis

Onychomycosis of Toenail

United States, Canada
Hisamitsu Pharmaceutical Co., Inc.

Completed

Safety & Efficacy Study of HTU-520 in the Treatment of Distal Subungual Onychomycosis of the Toenail

Onychomycosis

United States
Dow Pharmaceutical Sciences

Completed

The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Onychomycosis

United States, Canada
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

Chronic Myeloid Leukemia | Blast Crisis

Netherlands, United States, Italy, Austria, Canada, France, Germany, Singapore, Taiwan, United Kingdom, Australia, Korea, Republic of, Philippines, Sweden, Finland, Israel, Belgium, Denmark, Norway, Switzerland
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Chronic Myeloid Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-positive

Netherlands, United States, Italy, Argentina, Austria, Brazil, Canada, Germany, Peru, United Kingdom, France, Korea, Republic of, Sweden, Finland, Australia, Israel, Belgium, Denmark, Norway, Switzerland

Clinical Trials on Tinea Cruris in Norway

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations